Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by SanFrancisco99on Mar 19, 2015 10:52am

176 Views

Post# 23538254

RE:Since We Are Talking About Being Corrected

Dang! I even need to correct my correction here. Should have waited until I was done with the first cup of coffee.

It wasn't that the PSCK9 companies were touting that their RRR was lower than ours (as I stated in my correction). Instead, (as everyone knows) I was touting that our (208's) RRR was probably lower than theirs.... (and therefore wasn't that great)....

So I stand corrected again!

But you probably already knew all that!

Bullboard Posts

The Market Online’s Weekly Cannabis Report – Nov. 15, 2024